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ABSTRACT
We give results from a detailed analysis of human
Ribosomal Protein (RP) levels in normal and can-
cer samples and cell lines from large mRNA, copy
number variation and ribosome profiling datasets.
After normalizing total RP mRNA levels per sam-
ple, we find highly consistent tissue specific RP
mRNA signatures in normal and tumor samples. Mul-
tiple RP mRNA-subtypes exist in several cancers,
with significant survival and genomic differences.
Some RP mRNA variations among subtypes corre-
late with copy number loss of RP genes. In kidney
cancer, RP subtypes map to molecular subtypes re-
lated to cell-of-origin. Pan-cancer analysis of TCGA
data showed widespread single/double copy loss of
RP genes, without significantly affecting survival. In
several cancer cell lines, CRISPR-Cas9 knockout of
RP genes did not affect cell viability. Matched RP
ribosome profiling and mRNA data in humans and
rodents stratified by tissue and development stage
and were strongly correlated, showing that RP trans-
lation rates were proportional to mRNA levels. In a
small dataset of human adult and fetal tissues, RP
protein levels showed development stage and tissue
specific heterogeneity of RP levels. Our results sug-
gest that heterogeneous RP levels play a significant
functional role in cellular physiology, in both normal
and disease states.
INTRODUCTION
The human ribosome is composed of ribosomal RNA
(rRNA) and 80 structural ribosomal proteins (RPs), which
form its two subunits, 60S and 40S. RPs are essential in
early development in complex eukaryotes (1), and are highly
conserved. Furthermore, ribosomes from one species can
translate mRNA from different species (2). Interestingly, a
growing body of work suggests ribosome heterogeneity at
many levels, in response to extra/intra cellular stimuli, such
as differentiation/growth signals, tRNA abundance etc., to
optimize cell/tissue-specific objectives, such as translation
efficiency, selectivity and fidelity (reviewed in (3)). One of
the strongest evidence for existence of ‘specialized ribo-
somes’ comes from a study in mice, where loss of function
mutation in Rpl38 selectively perturbs translation of subsets
of Hox mRNA, while maintaining global protein synthesis
(4). Heterogeneity in RP mRNA levels in mouse embryonic
stem cells results in differential translation of sub-pools of
transcripts involved in metabolism, cell cycle and develop-
ment (5). Mass spectrometry data from budding yeast and
embryonic stem cells shows that RP stoichiometry varies
with environmental condition (6). In complex multicellu-
lar eukaryotes, the equivalent of ‘environment’ is the tissue
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microenvironment. Analysis of Encode data (7) and gene-
deletion data in yeast (8) shows environment/tissue-specific
regulation of mRNA levels of RP genes in eukaryotes (9). In
yeast, growth-defective 60S mutants increased synthesis of
proteins involved in proteasome-mediated degradation, and
40S mutants had increased translation of ribosome biogen-
esis genes (10).
The effects of alterations in RPs have also been noted in
cancers, with both germline and somatic mutations in RP
genes found in 10–30% of tumors (11). Ribosomopathies,
which are congenital dysfunctions in heart, bone, and kid-
ney, derive from mutations in different RPs, and make pa-
tients susceptible to cancers later in life (12,13). The fact
that specific germline RP mutations cause defects in spe-
cific tissues indicates tissue-specific roles for RP in dis-
ease. One may ask whether such heterogeneity exists only
in aberrant or disease conditions, or whether such varia-
tions are also found in normal tissues. The fact that riboso-
mal DNA (rDNA) has copy number variation (CNV) and
nucleotide differences within and among individuals, with
tissue-specific allelic expressions in functional regions of the
assembled ribosome (14) suggests that such tissue-specific
regulatory capacity of the ribosome may indeed be found
in non-diseased individuals.
Here, we asked whether there are consistent patterns
in RP heterogeneity in normal and cancer samples at the
mRNA and CNV level in humans. To address this, we ana-
lyzed the following large and well curated public databases:
1. Data from GTEx: consisting of mRNA levels for 11,688
normal samples for 53 human tissues from 714 subjects
(15),
2. Data from TCGA: consisting of mRNA levels in 10,363
tumor samples in 33 human cancer types (https://portal.
gdc.cancer.gov) and CNV data from 10,845 human tu-
mor samples (http://gdac.broadinstitute.org),
3. mRNA data from 675 tumor-derived human cell lines
(16),
4. CRISPR–Cas9 knockout data for viability/growth for
558 human cell lines (https://depmap.org),
5. Ribosome profiling and mRNA data from human (17–
20), mouse (17,21,22) and rat (23) tissues and cell cul-
tures,
6. Protein expression data from normal human adult and
fetal tissues (24).
After normalizing the mRNA data for overall (and unin-
teresting) inter-sample variation in total RP mRNA levels,
we found robust, highly tissue-specific mRNA signatures in
normal and tumor samples. At least three RP mRNA sig-
natures were necessary to capture the variation in RP levels
in non-diseased brain and blood samples, and at least six-
teen signatures were necessary to capture the variation in
RP mRNA levels in 53 different non-diseased tissue types.
Several cancer types had two RP mRNA subtypes, with sig-
nificantly different prognosis and genomic characteristics.
These RP subtypes mapped well to known molecular sub-
types, which, in some cases, had chromosomal deletions of
RP genes, which correlated with their low mRNA levels. A
pan-cancer analysis of CNVs in tumors showed that loss of
one or both copies of RP genes is common across cancer
types. CRISPR–Cas9 knockout of RP genes in several cell
lines showed that loss of several RPs does not always af-
fect cell viability. In humans, mice and rats, RNA-seq and
ribosome profiling data for RP genes in tissues and cell cul-
tures were highly correlated, showing that RP proteins are
being translated in the ribosome at levels proportional to
their mRNA levels. Consistently, both mRNA data and ri-
bosome profiling data of RP genes, normalized by total level
per sample, also showed tissue-specific and development-
stage–specific clusters. Finally, in a small dataset (24) of
protein expression levels in adult and fetal tissues, RP pro-
tein levels, standardized per sample, were found to be both
tissue- and development-stage–specific.
Overall, these results contribute to the extant literature
supporting ribosomal heterogeneity and suggest that func-
tionally heterogeneous ribosome populations may mean-
ingfully contribute to cellular physiology, with significant
heterogeneity in RP mRNA and CNV levels that are tissue-
and development-stage–specific.
MATERIALS AND METHODS
Data and normalization
RNA-seq read count data was obtained for 11,688 normal
tissue samples from GTEx (15) (v7p), 10,363 tumor sam-
ples from TCGA (NCI-GDC, v7), and 675 tumor-derived
cell lines from a recent study (16). The data was restricted to
genes that encode RPs known to be functional in humans
(25). The RP genes RPS4X and RPS4Y1/RPS4Y2, located
on the X and Y chromosome, were excluded, because they
have sex specific expression levels. Read count for each of
the 78 remaining RP genes (Supplementary Table S1a) was
divided by the length of the gene in kb, and further nor-
malized so that the sum over all 78 RP genes was the same
for each sample (Supplementary Figure S1a). The reason
for the second normalization is that different tissues have
different total numbers of ribosomes, and hence differ in
total RP mRNA levels. This trivial variation in overall RP
mRNA levels among tissues is not the focus of our analy-
sis. Instead, we are interested in potential variations in ra-
tios of RP mRNA levels among tissues. Making the sum
of reads per kb over the 78 RP genes the same for all sam-
ples removes the variation in total RP mRNA levels among
samples/tissues. The data normalized as above was used as
input for the t-SNE (26) and UMAP (27) analysis, but was
log2 transformed and standardized (z-score) for each RP
gene for the SOM analysis (28). GISTIC2 (29) copy number
variation (CNV) data for the 78 RP genes in 10 845 tumors
from 33 cancer types in the TCGA dataset was compiled
from ‘all thresholded.by genes.txt’ files downloaded from
Broad GDAC (http://gdac.broadinstitute.org), and the en-
tries −2 and −1 were interpreted as double deletion (aka
deep deletion) and single deletion (aka shallow deletion) re-
spectively.
Clustering methods overview
The goal of all clustering methods applied to
sample/feature data is to find ‘groups’ of samples and/or
features. The t-distributed Stochastic Neighbor Embedding
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or t-SNE (26) method is a popular method to identify clus-
ters in large datasets in an unsupervised manner. It projects
a high dimensional dataset into two dimensions by using
local Gaussian kernels so as to preserve local associations
of the data points in the original high dimensional space.
Given the large size (>10,000 samples) and high dimension
(78 dimensions) of the datasets analyzed, t-SNE was a
natural method of choice. To avoid method related biases
and reduce the possibility of overfitting, it is common to
validate clustering results using multiple clustering meth-
ods. The Uniform Manifold Approximation and Projection
or UMAP (27) method is an alternative to t-SNE which
uses a different kernel and claims to better retain the global
structure of the data. Self Organized Maps or SOM (28) is
another common method used to cluster data that is very
different from either t-SNE or UMAP. It uses an artificial
neural network to create a lower dimensional representa-
tion of the data by using competitive learning on the input
data vectors, while preserving topological features of the
input space. Matrix based algorithms, such as principal
component analysis (PCA) or Onco-GPS-Maps (30), are
effectively linear, whereas t-SNE, SOM and UMAP are
non-linear. Not all algorithms are equally efficient at find-
ing all clusters because they make different assumptions
about how to assign cluster membership. However, if the
clusters identified by different algorithms are consistent,
they are likely to represent real groupings in the data.
Methods for t-SNE (26), SOM (28) and UMAP (27)
The normalized dataset (Supplementary Figure S1a) was
analyzed by t-SNE and UMAP using the distance metric
d (i , j ) = ∑r |log2 (FC(i, j, r ))| where FC(i, j, r ) is the fold
change for the corresponding RP for sample pair (i, j ). The
index r takes Nr = 78 values corresponding to the number
of RPs and the indices i, j range from 1 to Ns, where Ns is
the number of samples used in the analysis. In the 2D pro-
jection from t-SNE, the samples were colored by tissue of
origin. To test whether the results are independent of the
chosen distance metric, we repeated the t-SNE analysis on a
log2 transformed version of the normalized dataset (Supple-
mentary Figure S1a) using nine different distance metrics:
‘cityblock’ (equivalent to using our original distance metric
on un-transformed data), ‘euclidean’, ‘seuclidean’, ‘cheby-
chev’, ‘minkowski’, ‘mahalanobis’, ‘cosine’, ‘pearson’ and
‘spearman’.
To test whether the same clustering holds when a different
clustering method is used, samples were mapped to hexag-
onal nodes using SOM in a 2D grid using the ‘kohonen’
package in R. The mapped nodes were colored by tissue of
origin using a majority rule: if >50% of the samples map-
ping to a node originated from a given tissue, that node was
assigned the color of that tissue. Thus, a co-localization of
nodes of the same color in SOM, and a clustering of samples
of the same color in t-SNE, would indicate that the observed
clusters are tissue-specific. The t-SNE analysis was done in
matlab via the function ‘tsne’ using the ‘exact’ algorithm,
and the distance metric mentioned above, with all other pa-
rameters set to default values. The SOM analysis used the
‘kohonen’ package (version 3.0.8) in R with the ‘rlen’ pa-
rameter set to 10,000 and other parameters set to default
values. The UMAP analysis used the GitHub python imple-
mentation at https://github.com/lmcinnes/umap, the same
data and the same distance metric as t-SNE with parameter
values: number neighbors: 20, min-dist: 0.5.
Methods for matrix factorization and the Onco-GPS-Map
(30)
To perform the Matrix-Factorization of the data using the
Onco-GPS-Map, the RP mRNA levels of the 78 × N ma-
trix of RPs × samples was converted to TPM (transcripts
per million bases), log2 transformed after adding 1 to each
entry, and standardized per sample. Finally, before each ma-
trix factorization, each row (RP) was re-scaled to the [0, 1]
interval over the samples being analyzed. In the matrix fac-
torization procedure, the data matrix M is decomposed into
the product of two matrices Mgenes × samples = Wgenes × k ×
Hk × samples. where W and H contain factors representing the
most salient gene- and sample-specific patterns in the input
matrix. In this way, for example, the blood and brain dataset
was decomposed into k = 3 NMF factors (RP mRNA sig-
natures) and the data matrix for pan-tissue analysis of all
53 tissue types was decomposed into k = 16 NMF factors.
The optimal number of clusters (optimum value of k) for
each data matrix was chosen as the number of clusters yield-
ing the highest consensus-clustering cophenetic correlation
(CCC) (30). The k columns of the W matrix represent the k
RP signatures (directions in the space of RP mRNA levels)
which best represent the data with k-factors. The columns
of the H matrix correspond to samples and the entries in
these k dimensional columns represent the contribution of
the corresponding factors in the W matrix to the sample.
The k factors and their contributions to the samples were
visualized by multi-dimensionally scaling the W and H ma-
trices to 2D, where the distances among the factors in the
projection to 2D are proportional to those in the original
k dimensions. The contribution of each RP in the factors
and the association of the samples to the factors were vi-
sualized by projecting them onto this 2D space based on
their amplitudes in the W and H matrix respectively. Fi-
nally, samples were colored by tissue type to visualize their
possible associations with factors. The computer codes that
implement the Onco-GPS-Map analysis are available at:
https://github.com/KwatME/model and infer.
TuBA (31) summary
Tunable biclustering algorithm (TuBA) is an unsupervised
algorithm that identifies modules of genes co-expressed in
subsets of samples at relatively higher (or lower) levels com-
pared to other samples in the dataset. TuBA requires spec-
ification of an ordered pair of parameters: (percentile cut-
off, overlap significance cutoff). The ‘percentile cutoff’ is the
fraction of samples in extremal sample sets for each gene,
and (ii) The ‘overlap significance cutoff’ is the FDR cut-
off for the association of each pair of genes to be consid-
ered relevant. For the GTEx dataset, the parameters were
set to (2%, 0.01). For the analysis of the cancer subtypes,
the parameters were set to (5%, 0.01) for LGG, SKCM,
BLCA, PRAD, CRC and (15%, 0.01) for UVM. To deter-
mine associations among samples in the biclusters, we used
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the hypergeometric test. All enrichments reported are at P-
value <0.001, FDR <0.01. Source code of TuBA is available
at: https://github.com/KhiabanianLab/TuBA. The gene co-
expression modules shown are the subset of genes forming
a complete subgraph/seed, which represents the linked core
of genes and samples forming a bicluster. The plots pre-
senting the biclusters were prepared using Cytoscape (32)
v3.7.0.
Identifying tissue-specific RP signatures in GTEx (15) data
Starting with the GTEx data normalized as described (Sup-
plementary Figure S1), five tissue types (cervix–endocervix,
cervix–ectocervix, fallopian tube, bladder, kidney cortex)
with less than 50 samples were discarded. To avoid tissue-
specific sampling biases due to unequal sample sizes among
tissues, from the remaining 48 tissues, 88 samples were ran-
domly selected per tissue without replacement, to create a
dataset D of 4,224 samples. The expression of each RP in
each tissue was compared to the expression of that RP in
D using the Wilcoxon Rank Sum test to compute a signifi-
cance P-value and log2 fold change. Using the significance
cutoff P-value <0.05, those RPs which did not have a statis-
tically significant log2 fold changes were assigned a log2 fold
change of 0. This resulted in a 78 × 48 tissue-specific RP sig-
nature matrix, where each row was an RP gene, each column
was a tissue, and the entries were modified log2 fold changes.
This analysis identified the top differential RPs across tissue
types (Supplementary Figure S6 and Table S1c). In addi-
tion, a 78 × 11,614 sample specific RP signature matrix was
generated, where each row was an RP gene, each column
an individual sample, and the entries were log2 fold change
compared to the median expression of that RP gene in D.
Spearman-Rho correlations and their P-values were com-
puted comparing the 78 × 48 tissue-specific RP signature
matrix to the 78 × 11,614 sample specific RP signature ma-
trix, and the Spearman Rho value was set to 0 for those RPs
with P-value ≥0.05. This generated a 11,614 × 48 consis-
tency matrix where each row was an individual sample, each
column was a tissue, and the entries are modified Spearman
Rho values. The heatmap (Supplementary Figure S7) of this
matrix shows that the RP signature of a tissue is represen-
tative of and highly correlated with the RP signatures of the
samples of that tissue type.
The Kaplan–Maier recurrence/survival curve
The non-parametric Kaplan–Maier (KM) method-
ology (33) was developed to study rates of
recurrence/death/response in situations where records
were incomplete, i.e. in situations where, during the course
of the study, patients either left the study, were not traceable
or died from causes other than the disease in question. The
data used in the KM analysis is a list of time of events (say
disease recurrence) with each event labeled as a true event
(recurrence) or a censoring event (loss of information for
a given patient). From a defined initial time (say the end
of surgery and radiation in the case of cancer patients),
survival or recurrence times are measured for a cohort of
patients to the occurrence of a given event, which might
be the time of treatment to a recurrence/death event in
a cancer patient. A survival time is called censored when
the event has not yet happened but there is no more
information on the patient for time points beyond this one,
as may happen if a patient drops out of a study before
the end of the study period. The survival or recurrence
function S(t) is defined as the probability of recurring
after or surviving until at least time t. The graph of S(t)
against t is called the KM recurrence or survival curve. The
Kaplan–Meier method can be used to estimate this curve
from the observed survival times without the assumption
of an underlying probability distribution. KM plots are
commonly used in case/control studies, clinical trials, and
pharmaceutical drug efficacy studies to compare two or
more defined groups of patients.
Ribosome profiling and RNA-Seq data for humans and ro-
dents
The ribosome profiling databases HRPDviewer (34)
and RPFdb (35) were searched to identify human
and rodent datasets with translation data in multi-
ple tissue/cell-types, and the following RNA-seq (i.e.
mRNA expression) data and ribosome profiling (i.e.
transcripts being translated in ribosomes) data sets were
downloaded from the Gene Expression Omnibus (GEO,
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=): hu-
man (GSE60426 (17), GSE62247 (18), GSE65885 (19,20)),
mouse (GSE60426 (17), GSE41246, GSE72064 (21),
GSE89108 (22), rat (GSE66715 (23)). Synonyms and anno-
tations from NCBI (https://www.ncbi.nlm.nih.gov/gene/),
Ensembl (https://www.ensembl.org/biomart/martview/),
UCSC (http://genome.ucsc.edu/cgi-bin/hgTables) and
UniProt (https://www.uniprot.org/uniprot/) were used to
restrict the downloaded RNA-seq and ribosome profiling
data to the 78 RP genes (Supplementary Table S1a) or a
subset thereof (since not all datasets had data of all 78 RP
genes). If a dataset had multiple rows for the same RP
gene, they were aggregated so that there was only one row
per RP gene. Both RNA-seq and ribosome profiling data
of RP genes were normalized as previously described (Sup-
plementary Figure S1a), i.e. corrected for gene length (if
necessary) and then normalized to make the sum of reads
over all RPs the same for every sample. This normalization
eliminates the uninteresting and expected overall variation
in total RP levels among tissues and cell-lines.
To minimize batch effects, two 48 h B-cell samples were
excluded from GSE60426 as they were cultured differently
from the rest (17). In GSE62247, most samples were sub-
mitted to GEO on 10 October 2014 but a few were submit-
ted on 2 July 2015. The latter were also excluded to reduce
batch effects.
RESULTS
Normal and tumor samples from humans have heterogeneous
RP mRNA signatures
RNA-Seq mRNA data was obtained from (i) GTEx (15)
(https://gtexportal.org/home/datasets): 11,688 normal sam-
ples from 53 normal tissue types from 714 non-diseased in-
dividuals; (ii) The Cancer Genome Atlas (TCGA) (https:
//portal.gdc.cancer.gov/repository): 10,688 tumor samples
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across 33 solid cancer types and (iii) 675 cell lines (16).
The data was restricted to the 80 RPs that form the hu-
man eukaryotic ribosome (25), and the three datasets were
analyzed separately to avoid batch effects. Data for the RP
genes RPS4X and RPS4Y1/RPS4Y2, located on chromo-
somes X and Y, respectively, was excluded because of their
sex-specific effects. The read counts for the remaining 78 RP
genes (Supplementary Table S1a) were normalized by gene
length, and then rescaled to make the sum of RP mRNA
levels the same in each sample (Methods, Supplementary
Figure S1a). This normalization eliminates the uninterest-
ing variation in total RP mRNA levels among samples.
Projection of the normalized data to 2D using t-SNE (26)
showed multiple tissue-specific clusters for normal and tu-
mor samples (Supplementary Figure S1b,c), indicating het-
erogeneity of RP mRNA signatures. In contrast, cell lines
derived from many different cancer types showed only one
cluster (Supplementary Figure S1d). Similar results were
observed in t-SNE analysis using nine distance metrics (data
not shown), showing that the results are not sensitive to the
choice of distance metric.
The RP mRNA signature in normal human samples is tissue-
specific
The t-SNE clusters for normal samples (Supplementary
Figure S1b) mapped to different tissues (Figure 1). Brain
tissue formed two clusters, one for the cerebellum and cere-
bellar hemisphere, and one for other brain tissues: cortex,
ganglia, amygdala, hippocampus, hypothalamus, substan-
tia nigra, and spinal cord, while pituitary, nerve, blood,
transformed lymphocytes and spleen samples clustered sep-
arately (Figure 1A). Samples from the stomach, small in-
testine, terminal ileum and transverse colon clustered to-
gether, as did samples from esophagus-muscularis, gastro-
esophageal junction, and sigmoid colon, while samples
from esophagus-mucosa, liver and pancreas clustered sepa-
rately (Figure 1B). Endocrine system samples (Figure 1C)
had distinct clusters for pituitary, thyroid, adrenal, pan-
creas, ovary and testis. Soft tissue samples had distinct clus-
ters for adipose, skin, arterial, heart, skeletal muscle, and
transformed fibroblasts samples (Figure 1D). Similar re-
sults were observed in t-SNE analysis using nine distance
metrics (data not shown), showing that the results are not
sensitive to the choice of distance metric. Independent, un-
supervised analysis of samples from each of Figure 1A–
D using Self-Organized-Maps (SOM) (28) confirmed this
tissue-specific clustering (Figure 1E–H). As further valida-
tion, independent analysis of the full GTEx (15) dataset us-
ing UMAP (27) again confirmed the tissue-specific cluster-
ing (Supplementary Figure S2).
To study whether these tissue-specific RP clusters map
to specific RP signatures, we applied the matrix factoriza-
tion algorithm Onco-GPS-Map (30) (see Methods) to the
GTEx data. Three RP signatures (factors) were needed to
capture the variation in blood and brain samples (Figure
2A, B, Supplementary Table S1b), and 16 signatures were
necessary for the 53 GTEx tissue types (Supplementary Fig-
ure S3a, b). Each tissue type mapped to combinations of
RP factors (Figure 2C, Supplementary Figure S4) and the
three factors for blood and brain were linear combinations
of the sixteen factors for 53 normal tissue types (Supple-
mentary Figure S3c). Figure 2D–F shows the RP genes
up/down regulated among blood, cerebellum and cerebel-
lar hemisphere and brain (rest) clusters in pairwise compar-
isons. Note that, although some of the fold changes in these
plots are modest, the large sample sizes make them highly
significant. Also note that the differentially expressed RPs
shown in Figure 2D–F are consistent with the signatures
F0, F1, F2 in Figure 2A and Supplementary Table S1b. As
further validation of these findings, biclustering analysis of
the blood-brain GTEx data by TuBA (31) identified two ro-
bust modules of RP genes with significantly higher/lower
mRNA levels in subsets of samples (Supplementary Figure
S5), which clearly corresponded to factors F1 and F0 for
blood and cerebellum/cerebellar-hemisphere tissues respec-
tively (Figure 2A, Supplementary Table S1b). These results
show that RP mRNA signatures in normal human samples
are tissue-specific, with different tissues displaying different
combinations of RP mRNA signatures.
Supplementary Figure S6 (and Supplementary Table
S1c) shows tissue-specific RP signatures in the GTEx data,
where the highest/lowest log2 fold changes of five RPs in
each tissue are shown in red/blue respectively, compared to
their median expression across tissue types (details in Ma-
terials & Methods). Supplementary Figure S7 shows that
the RP signature of a tissue (Supplementary Figure S6 and
Table S1c) is representative of and highly correlated with
the RP signatures of individual samples of that tissue type.
Note also that tissue types that clustered together in Figure
1 have very similar RP signatures.
The RP mRNA signature in human tumor samples is tissue-
specific
Inspection of TCGA t-SNE clusters (Supplementary Fig-
ure S1c) also showed stratification by tissue (Figure 3A–
F). Nervous and immune system tumors showed sepa-
rate clusters for glioblastoma (GBM), low-grade glioma
(LGG), pheochromocytoma/paraganglioma (PCPG), thy-
moma (THYM), diffuse large B-cell lymphoma (DLBC),
and acute myeloid leukemia (LAML) (Figure 3A). Diges-
tive system tumors showed separate clusters for colorec-
tal (CRC), gastric/esophageal (STES), pancreatic (PAAD),
liver (LIHC), and head-neck squamous (HNSC) can-
cers (Figure 3B). Endocrine system tumors had separate
clusters for thyroid (THCA), adrenocortical (ACC), pan-
creatic (PAAD), ovarian (OV) and testicular germ cell
(TGCT) cancers (Figure 3C). Urinary system tumors strat-
ified into bladder cancer (BLCA) and the renal cancer
subtypes: clear-cell (KIRC), papillary (KIRP) and chro-
mophobe (KICH) (Figure 3D). Cancers of the prostate
(PRAD), breast (BRCA), ovary (OV), cervix (CESC), and
endometrium (UCEC) formed distinct clusters (Figure 3E),
while melanoma of the skin (SKCM) and eye (UVM) had
two clusters each (Figure 3F). Similar results were observed
in t-SNE analysis using nine distance metrics (data not
shown), showing that the results are not sensitive to the
choice of distance metric. Independent unsupervised anal-
ysis of each group of samples in Figure 3A–F by SOM
(28) confirmed this tissue-specific clustering (Figure 3G–
L). Analysis of the full TCGA dataset using UMAP (27)
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Figure 1. Normal samples have tissue-specific RP mRNA signatures. (A–D) t-SNE (26) analysis of GTEx (15) RP mRNA data for 11,688 normal samples
from 53 tissue types. Each panel shows a subset of the full t-SNE plot, with samples stratified by organ system: (A) nervous and immune system, (B)
digestive system, (C) endocrine system, (D) soft tissues. (E–H) Self-Organizing Maps (28) (SOM) applied to samples in A–D validate the stratification seen
by t-SNE. Nodes marked NA had no tissue-specific majority and empty nodes had no samples mapped.
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Figure 2. RP mRNA levels in blood and brain have three distinct signatures. Matrix factorization analysis of the GTEx (15) blood and brain RP mRNA
data using Onco-GPS-Map (30) showed that three RP signatures (factors) are optimal by consensus-clustering cophenetic correlation (CCC). The algorithm
factorizes the 78 × N matrix M of mRNA levels of RPs × samples as M = W × H, where W is a 78 × k matrix and H is a k × N matrix (Supplementary
Table S1b). (A) Heatmap of the W matrix (standardized by rows) showing the three RP signatures corresponding to three factors F0, F1, F2. (B) Heatmap
of the H matrix (standardized by columns) showing the contribution of the three factors for each sample in the data. The samples for blood, cerebellar
brain and rest of brain tissues use almost distinct factors. (C) A visualization of the data by multi-dimensional scaling of the W and H matrices to 2D.
(D–F) Volcano plots for up/down regulated RP genes in blood, cerebellum and cerebellar hemisphere, and brain (rest) clusters pairwise; differential RPs
are consistent with the signatures F0, F1, F2 in (A).
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Figure 3. Tumor samples have tissue-specific RP mRNA signatures. (A–F) t-SNE (26) analysis of RP mRNA data from 10 363 TCGA samples for 33
cancer types shows tissue/cancer type specific clusters. Each panel shows a subset of the full t-SNE plot with samples stratified by organ system: (A)
cancers of the nervous and immune system, (B) cancers of the digestive system, (C) cancers of the endocrine system, (D) cancers of the urinary system, (E)
sex-specific cancers, (F) melanomas. (G–L) Self-Organizing Maps (28) (SOM) applied to samples in A–F validate the stratification seen by t-SNE. Nodes
marked NA had no tissue-specific majority and empty nodes had no samples mapped. Tumor acronyms are listed in Supplementary Table S1j.
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also confirmed the tissue-specific clustering (Supplemen-
tary Figure S8).
Note that, because of the normalization that equalized
the total RP mRNA level in each sample, these clusters re-
flect true tissue-specific variation in RP mRNA levels in tu-
mors. These clusters are not the result of differences in total
RP expression levels in tissues, which is not of interest be-
cause it would merely reflect different rates of overall ribo-
some activity.
Pan-cancer analysis of RP copy number variation (CNV)
data for 10,845 tumor samples from TCGA by t-SNE
showed no separation by tissue/cancer type (data not
shown), except for kidney cancer, where the samples clus-
tered into the three known subtypes (KIRC, KIRP and
KICH) (36–38), which have distinct cells of origin in
the kidney (39,40). RP genes with significantly high/low
mRNA levels in KIRP or KICH versus KIRC also had
significant copy number gains/losses (Supplementary Fig-
ure S9). While most KIRC tumors have single copy
loss of chromosome 3p (36), ∼10% lose both copies,
with complete loss of RPL14, RPL15, RPL29, RPL32,
RPSA.
Six cancers have RP mRNA subtypes with distinct prognosis
and genomic characteristics
Several TCGA cancer types had multiple RP mRNA sub-
clusters by t-SNE (26) (Figure 3A–F), suggesting the exis-
tence of RP subtypes with distinct RP mRNA signatures.
Clinical data from TCGA (41) showed that in six of these
cancer types, the RP subtypes had significant disease asso-
ciated survival differences: for disease specific survival in
LGG, SKCM, UVM, BLCA, CRC (COAD and READ),
and disease free interval in PRAD (Figure 4a) at P-value
< 0.05 by two-sided log-rank tests (Supplementary Table
S1d). Several RP genes (Figure 4B, Supplementary Table
S1e) had significantly higher mRNA levels in the RP sub-
types with worse/better prognosis. Biclustering analysis of
the data for these six cancer types by TuBA (31) identified
sets of co-expressed RP genes up-regulated in subsets of
samples (Supplementary Figure S10), which matched the
differentially expressed RP genes (Figure 4B). The sam-
ples in the biclusters also had a strong overlap with the
better/worse prognosis RP subtypes (Supplementary Table
S1d). These findings complement and extend results noted
in recent literature (42,43).
If different RPs are indeed associated with different sur-
vival or phenotypic outcome, we should be able to see other
signatures of such association in human populations. In
these six cancer types, the RP genes over-expressed in the
better prognosis RP subtypes (Supplementary Table S1e)
were intolerant of loss-of-function (LoF) variation, as mea-
sured by the ‘probability of loss of intolerance’ (pLI) score
(44) (Figure 4C). pLI scores range from 0 to 1, and estimate
the probability that a given gene is haplo-insufficient. Genes
with high pLI scores (e.g. Mendelian disease genes) are LoF
intolerant, whereas genes with low pLI scores are LoF tol-
erant. The RP genes over-expressed in the worse prognosis
RP subtypes in the six cancer types described above were
more tolerant of loss-of-function (LoF) variation, i.e. had
lower pLI scores.
Using genomic, transcriptomic, and histologic data from
TCGA (45–49) and mutation data from cBioPortal (50,51)
(http://www.cbioportal.org), we studied molecular differ-
ences among the RP subtypes. In LGG, SKCM and BLCA,
the RP subtypes overlapped substantially with known
molecular subtypes (Supplementary Figure S11a). The
LGG-worse survival RP mRNA subtype was enriched in
the ‘IDH-mutant 1p/19q non-co-deletion tumors’, ‘IDH-
wildtype tumors’, and tumors with ‘astrocytoma histology’,
while the LGG-better survival RP mRNA subtype was en-
riched in the ‘IDH-mutant 1p/19q co-deletion tumors’, and
tumors with ‘oligodendroglioma histology’ as defined in the
literature (45). The SKCM-worse survival RP mRNA sub-
type was enriched in the ‘keratin subtype’ while the SKCM-
better survival RP mRNA subtype was enriched in ‘MITF-
low subtype’ or ‘immune subtype’ as defined in the literature
(46). The BLCA-worse survival RP mRNA subtype was en-
riched in ‘basal squamous’, ‘neuronal’, ‘luminal-infiltrated’
tumors while the BLCA-better survival RP mRNA sub-
type was enriched in ‘luminal papillary’ and ‘luminal’ tu-
mors, and tumors with ‘papillary histology’ as defined in the
literature (48). In LGG, UVM, BLCA, PRAD, and CRC,
there were also other significant genomic differences (at P-
value < 0.05 by two-sided Fisher’s exact tests) among the
RP mRNA subtypes (Supplementary Figure S11b).
In LGG, UVM and BLCA, the majority of differences in
RP mRNA levels among the subtypes were due to CNVs in
RP genes (Supplementary Figure S12a). Heatmaps of copy
number data for these RPs (Supplementary Figure S12b)
show that mRNA differential expressions (Supplementary
Figure S12a) correlate with copy number alterations. For
example, RP genes RPL5, RPL11, RPL22, RPS8 on chro-
mosome 1p, and RPL13A, RPL18, RPL28, RPS5, RPS9,
RPS11, RPS16, RPS19 on chromosome 19q are co-deleted
in the better prognosis RP mRNA subtype in LGG (Sup-
plementary Figure S12b), and these genes have signifi-
cantly lower mRNA expression levels (Supplementary Fig-
ure S12a).
Double/single deletions of RPs are common in human tumors
Pan-Cancer analysis of TCGA CNV data showed that 1,272
(11.7%) tumors had double deletion of one or more of the
78 RP genes, and both copies of each of the 78 RP genes
were deleted in at least one tumor in the TCGA data (Fig-
ure 5A, B). RPL13 and RPL29 had double deletions in
more than 100 samples (Figure 5A, B) and both copies of
up to 16 RPs were lost in one sample (Figure 5C). Double
deletions of RP genes were observed in all 33 cancer types
(Figure 5D), but were more frequent in some cancer types
than others (Supplementary Figure S13, Table S1f). DLBC
was at one extreme, where over 25% of tumors had double
deletion of some RP gene, and KICH was at the other ex-
treme, where <2% tumors had double deletion of some RP
genes. Highly recurrent, double deletion of an RP gene was
rare, and only one RP in DLBC (RPS12) and five RPs in
KIRC (RPL14, RPL15, RPL29, RPL32, RPSA) were dou-
ble deleted in >10% of tumors (Supplementary Figure S13,
Table S1f).
Overall, 8,910 (82.2%) tumors had single/double deletion
of one or more of the 78 RP genes in the TCGA dataset.
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Figure 4. Tumors from distinct clusters for the same cancer type have significantly different prognosis. t-SNE (26) analysis of RP mRNA data for TCGA
samples (Figure 3A–F), showed multiple subtypes (clusters) in several cancer types. In six of these cancers, there were significant differences in prognosis
between these subtypes: low-grade glioma (LGG), skin melanoma (SKCM), eye melanoma (UVM), bladder cancer (BLCA), prostate cancer (PRAD) and
colorectal cancer (CRC). (A) Kaplan–Meier plots showing significant differences in disease specific survival or disease-free interval among the RP-subtypes
in LGG, SKCM, UVM, BLCA, CRC and PRAD at P < 0.05 by two-sided Wilcoxon rank-sum test. (B) Volcano plot identifies RP genes with significantly
different mRNA levels among the RP-subtypes by two-sided Wilcoxon rank-sum tests. Green/red colors represent RPs upregulated in the better/worse
prognosis subtypes (Figure 4a, Supplementary Table S1d). (C) In all six cancer types, the RP genes over-expressed in the better prognosis subtype (Figure
4B, Supplementary Table S1d) were highly intolerant of loss-of-function (LoF) variation, as evidenced by a high ‘probability of loss of intolerance’ (pLI)
scores (44). Similarly, RP genes over-expressed in the worse prognosis RP-subtype were tolerant of loss-of-function variation, with relatively lower pLI
scores.
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Figure 5. Double deletions of RP genes is common in TCGA tumors. (A) The number of tumors with double deletion of an RP gene in the TCGA dataset.
Each RP gene had double deletion in at least one tumor sample. (B) Double deletion profile of the RP genes for TCGA samples with at least one RP
double deletion. (C) Distribution of double deletions of RPs across tumors. Double deletion of one to sixteen RP genes is seen in the same tumor sample.
(D) Distribution of RP double deletions across cancer types. All 33 cancer types in TCGA have double deletion of multiple RPs. Serous ovarian cancer
(OV) had 62 RPs with double deletions in combinations across samples.
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Individual RP genes had single/double deletion in 392–
4,013 tumors (Supplementary Figure S14ab), and up to 55
RPs had single/double deletions in the same sample (Sup-
plementary Figure S14c). Single/double deletions of RP
genes were abundant in all 33 cancer types (Supplemen-
tary Figure S14d) but were more frequent in some cancer
types than others (Supplementary Figure S15, Table S1g).
OV was at one extreme, with over 99% of tumors show-
ing single/double deletion of some RP genes, and LAML
was at the other extreme, with <20% of tumors showing
single/double deletion of some RP genes. Highly recurrent
single/double deletion of a RP gene was quite common
(Supplementary Figure S15, Table S1g), and there were even
examples of RP genes single/double deleted in over 85% of
tumors in a given cancer type, such as RPS15 in OV, RPL29
in LUSC, RPS24 in GBM, RPL17 in READ; and RPL14,
RPL15, RPL29, RPL32, RPSA in KIRC.
In most cancer types, there was no significant association
between the number of double-deleted RP genes in tumors
and patient survival (Supplementary Figure S16), showing
that RP loss did not reduce tumor fitness.
CRISPR–Cas9 knockout of RPs shows that loss of some RPs
does not affect cell viability in several human tumor-derived
cell lines
Data from CRISPR–Cas9 screens across 558 cancer cell
lines (https://depmap.org) were analyzed for ‘Essentiality’
of the 74 RP genes for which data was available. ‘Essen-
tiality’ of a gene was estimated using CERES (52), which
estimates gene-Dependency Scores (gDS) (53,54), after ac-
counting for copy number variation, using sgRNA abun-
dance in a reference pool. ‘Strictly essential genes’, whose
deletion severely affects cell viability, have gDS < −1.
‘Strictly non-essential genes’, whose deletion has no effect
on cell viability, have gDS > 0. Genes with gDS between −1
and 0 are ‘potentially non-essential’, i.e. their deletion af-
fects cell viability to some degree but is not lethal. Since the
cell lines spanned cancers from over 25 tissue types, this data
represents RP single-knockout effects across cellular/tissue
contexts.
If all RPs are essential, their gDS should always be
<−1. Instead, 73 of the 74 RPs (all except RPS20), had
gDS >−1 in one or more cell lines (Figure 6A, B; Sup-
plementary Table S1h). Every cell-line, irrespective of the
cancer type, had some RP genes with gDS >−1, and the
minimum/maximum number of RPs with gDS >−1 in a
single cell line varied from 21 to 62, with a mode of 35 (Fig-
ure 6C). RP genes with gDS >−1 were abundant in every
cancer type, as between 51 and 68 RPs had gDS >−1 in
different cancer types (Figure 6D). Supplementary Figure
S17 and Table S1i show the frequency (%) of gDS >−1 for
each RP (shown in rows) in various cancer types (shown in
columns). Unlike the corresponding data for single/double
deletion (Supplementary Figure S15, Table S1g) there was
very little inter-cancer variation for a given RP. Many RPs
(the top ∼40% in Supplementary Figure S17) frequently
have gDS >−1 independent of cancer type, showing that
these RP deletions are tolerated in many different cell lines
across cancer types. Conversely, many RPs (the bottom
∼45% in Supplementary Figure S17) rarely had gDS >−1,
independent of cancer type, showing that these RPs are es-
sential for growth in many different cell lines across cancer
types. These differences in the essentiality of RP genes in
cell lines versus RP copy number loss in tumors is in accor-
dance with the tissue-specific clustering seen in tumors but
not seen in cell lines.
Forty-four RPs were strictly non-essential (gDS > 0) in
at least one cell line. Five RPs: RPL21, RPL22, RPL35A,
RPS10, RPS26, were strictly non-essential in more than 25
cell lines, and RPL22 and RPL21 were strictly non-essential
in 223 and 444 cell lines respectively (Supplementary Fig-
ure S18a, b; Table S1h). While most cell lines had only 0–5
RPs with gDS > 0, 43 RPs were strictly non-essential in
one gastric cancer cell line (Supplementary Figure S18c),
and non-essentiality of RPs was found in cell lines from all
cancer types (Supplementary Figure S18d). There was no
correlation/clustering of RP gDS values and tissue of origin
(data not shown), indicating that the role of RPs in survival
of cell lines does not depend on tissue of origin.
Ribosome profiling and RNA-Seq data for RPs are highly
correlated in human and rodent tissues and cell cultures
To address whether tissue-specific RP mRNA level differ-
ences, which represent transcribed but not translated pools
of RP mRNA, actually correspond to the levels at which
these mRNA pools are translated in ribosomes, we ana-
lyzed mRNA expression data from RNA-Seq, which rep-
resents transcription levels, and ribosome profiling data,
which represents levels at which these transcripts are being
translated in the ribosome, in matched samples across a va-
riety of tissues and cell cultures for human (17–20), mouse
(17,21,22) and rat (23) (details in Materials and Methods).
Each of these datasets were normalized using the protocol
in Supplementary Figure S1a.
Scatter plots of normalized translation levels of RP genes
from ribosome profiling versus mRNA expression levels
of RP genes from RNA-seq for the same cells/tissues for
human, mouse and rat are shown in Figure 7A–G. They
show highly consistent covariation of translation level of RP
genes and their mRNA expression levels in every tissue/cell-
type. We also see (Figure 7H) strong, consistent and statis-
tically significant (P < 10−4) correlation between mRNA
expression level and translation level of RP genes in every
sample. These results show that the ribosome is translating
RP transcripts at levels proportional to their mRNA levels.
Furthermore, the translated RP transcripts are also tis-
sue (Supplementary Figure S19a–d), developmental-stage
(Supplementary Figure S19e–g) and environment specific
(Supplementary Figure S19h). As expected from Figure
7, the ribosome profiling results shown in Supplementary
Figure S19 are in strong agreement with results from RP
mRNA levels (Supplementary Figure S20) of the corre-
sponding matched samples. The mRNA expression levels of
RP genes in these samples are also tissue-specific (Supple-
mentary Figure S20a–d), and developmental-stage specific
(Supplementary Figure S20e–g). Note that the RNA-Seq
plot corresponding to Supplementary Figure S19h is miss-
ing because RNA-seq data was available only for untreated
control samples.
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Figure 6. Essentiality of RP Genes under CRISPR-Cas9 knockout in 558 cancer cell lines. CRISPR–Cas9 essentiality screen data for 74 RP genes for
558 cancer cell lines using the computational tool CERES (52). Genes with a dependency score (53,54) (gDS) greater than −1 are considered potentially
non-essential. (A) Number of cell lines with gDS >−1 for each RP. Seven RPs had gDS > −1 in every cell line and 73 RPs had gDS >−1 in at least one
cell line. (B) gDS profile of the RP genes in cell lines. Blue indicates gDS >−1 in the sample. (C) Distribution of number of RP genes with gDS >−1 across
cell lines. Every cell line had at least 21 RP genes with gDS >−1. While 35 RPs with gDS > −1 was the most common, as many as 62 RP genes had gDS
>−1 in a gastric cancer cell line (ACH-000167). (D) Number of RPs with gDS >−1 for cell lines stratified by cancer type.
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Figure 7. Comparison of mRNA levels (RNA-Seq) and ribosome profiling levels for RP genes. (A–G) Scatter plot of matched mRNA (measured by
RNA-seq) and ribosome profiling levels (showing level of transcripts being translated) for RP genes in various tissues/cell-types. Median value is shown
for tissue/cell-type with multiple samples. The axes are in log2 scale. RPF = ribosome protected fragment, hES = human embryonic stem cells grown
in a feeder free protocol that maintains pluripotency, NDx = human embryonic stem cell grown for x days in a neural conversion protocol that induces
cell differentiation. (H) Spearman Rank Correlation of mRNA and ribosome profiling levels of RP genes for paired samples shows highly consistent
covariation and highly significant correlation (P < 10−4) of mRNA and ribosome profiling levels for RP genes in each individual sample.
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RP protein abundance levels in humans are developmental-
stage and tissue-specific
To test whether the tissue specificity of RPs at the mRNA
level is also seen at the protein level, protein expression data
for 77 RP genes in 17 adult tissues, 7 fetal tissues and 6 pu-
rified primary haematopoietic cells from histologically nor-
mal human samples were obtained from a recent study (24).
The data was log-transformed and standardized (z-score)
to eliminate global variation in overall RP protein levels
among tissues. Principal component analysis (PCA) of the
data cleanly distinguished fetal from adult tissues (Figure
8A). Consistently, the same tissue type had different RP
protein signatures in adult and fetal tissue (Figure 8B). Us-
ing the Spearman Rho rank correlation S as a measure of
similarity, the pairwise difference in RP protein signatures
were compared among tissues. If the protein composition
of ribosome were invariant, 1-S should be near zero for all
tissue-pairs. Instead, this quantity was substantially differ-
ent from zero for several tissue-pairs (Figure 8C). Consis-
tently, both adult tissue-pairs and fetal tissue-pairs showed
differential RP protein signatures (Figure 8D). These results
suggest that, similar to RP translation levels measured by ri-
bosome profiling, RP protein levels are also developmental-
stage (adult versus fetus) and tissue type specific.
DISCUSSION
We analyzed a variety of large datasets using several analyt-
ical methods to study the heterogeneity of mRNA expres-
sion levels and copy number variations of ribosomal pro-
teins (RPs) in normal human tissues, cancer samples and
cell lines. Our overall conclusion from this analysis, as well
as from CRISPR-Cas9 knockout of RPs in human cancer
cell lines, protein abundance of RPs in normal human tis-
sues, matched ribosome profiling and mRNA data of RPs
for human, mouse and rat tissues and cell cultures, is that
transcriptomic, translatomic, and proteomic levels of RPs
are highly variable, with strong and consistent tissue, envi-
ronment, and development-stage–specific signatures. In six
cancer types, there are clusters of samples with distinct RP
mRNA signatures associated with differential patient sur-
vival. Finally, double copy losses of RPs in tumors, and
CRISPR-Cas9 knockout of several RPs in cell lines, do not
lead to loss of ribosome function.
The major question that arises from our analysis is
whether the human ribosome must have the same protein
composition in all cells and tissues under all conditions to
be able to function? One possible but speculative and un-
proven explanation of our results is that ribosomal compo-
sition is variable, and depends on tissue/cell, environment,
and development stage. We note that although this is the
simplest explanation of our results, this hypothesis needs to
be experimentally validated.
We discuss our findings below in greater detail, note their
significance and shortcomings, carefully separate facts from
speculation, and provide alternative explanations of our re-
sults where possible.
Fact I: TCGA CNV data showed that double deletion of
each of the 78 non-sex-specific RP genes is found in one
or more tumors (Figure 5A and B). Nearly 12 percent of
tumors had double deletion of an RP gene while retain-
ing ribosome functionality. Double deletions of up to 16
RPs were tolerated in the same tumor (Figure 5C), with
RPL13 deleted in 159 tumor samples across various cancer
types (Figure 5A and B). Furthermore, there was no cor-
relation between number of double deleted RPs in tumors
and patient survival (Supplementary Figure S16) in most
cancer types, suggesting that ribosome function is not com-
promised by such losses of RP genes.
Speculation I: These copy number variations would sug-
gest that at least in tumors, the ribosome can function with-
out all its RP components, which would suggest that the
ribosomal protein stoichiometry in tumors is not neces-
sarily 1:1:1. . . for all RPs. An alternative explanation of
these results is that the TCGA CNV data is just incor-
rect. This seems highly unlikely since the TCGA CNV data
used in this study was inferred from Affymetrix Genome-
Wide Human SNP6 Array by Broad Institute (http://gdac.
broadinstitute.org) using GISTIC2 (29), a method whose
accuracy has been tested and validated in real and simulated
datasets (29). Although it is possible that unlike other genes
RPs present some unique challenges in inferring CNV, we
cannot imagine why this would be the case. Another possi-
ble explanation is that even if the RP gene is indeed deleted,
the missing RP gene would be replaced by a parolog (6) or
pseudogene and the protein stoichiometry of the ribosome
remains 1:1:1. . . for all RPs.
Fact II: CRISPR–Cas9 knockout data for RPs in 558
cancer cell lines showed that only RPS20 was strictly essen-
tial in these cell lines, only 22 RPs were strictly essential in
more than 500 cell lines, and only 39 were strictly essential in
most cell lines (Figure 6, Supplementary Table S1h). RPL21
and RPL22 were strictly non-essential (no loss in viability or
growth of cell line from knockout) in 444 and 223 cell lines
respectively. These results show that not all RPs are essen-
tial in cancer cell lines, and several RPs can be knocked out
without complete loss of ribosome function.
Speculation II: These results suggest that ribosome func-
tion is retained in many tumor-derived cell lines after
CRISPR single knockout of several RPs. However, there are
many off target effects in CRISPR knockout studies (55),
so it is possible that the signal we see may be misleading. A
repeat CRISPR knockout experiment along the same lines
with RP genes as the only target would be a valuable test.
However, such off-target activity depends on guide RNA
sequences and experimental conditions. The guide RNAs
used in the CRISPR knockout screens used in the study
from where the data were derived were designed to mini-
mize off-target activity (56), and the inferred dependency
data was quality controlled using non-targeting controls
and bench marked against a gold-standard set of core essen-
tial and non-essential genes (57). Moreover, CERES anal-
ysis corrects for association between copy number effects
and sgRNA scores improving false discovery rates associ-
ated with CRISPR screens (52).
Fact III: t-SNE (26), SOM (28), and UMAP (27) anal-
ysis of RP mRNA levels for 11,688 normal samples from
GTEx (15) and 10,363 tumor samples from TCGA, nor-
malized to eliminate overall (global) variation in total RP
expression level among samples (Materials and Methods),
showed that the samples clustered by tissue type (Figures
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Figure 8. RP protein levels in humans are developmental-stage and tissue type specific. (A) Principal component analysis (PCA) of log-transformed and
standardized human RP protein levels for 30 histologically normal human samples cleanly distinguished fetal tissues (green) from adult tissues (blue/red
for solid/liquid tissues). (B) Tissues had differential RP protein levels for liver and heart in adult vs fetus in humans. Dotted lines are |zx – zy | = 1, and
labeled RPs have |zx – zy | > 1.25. (C) Heatmap of 1 – S, where S = Spearman Rho rank correlation, shows that although all pairs of tissues are significantly
correlated (S > 0.4, P < 0.001), they are far from identical (S = 1) and can be substantially different (e.g. some tissue-pairs have 1 – S > 0.5). (D) Adult
and fetal tissue from different organs show differential RP protein levels. Dotted lines are |zx – zy | = 1, and labeled RPs have |zx – zy | > 1.25.
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1 and 3, Supplementary Figures S2 and S8). Similar analy-
sis of 675 tumor derived cell lines (16) showed no clustering
by tissue. This also agrees with the CRISPR–Cas9 deletion
screen results, where there was no correlation between RP
essentiality and tissue type in cell lines.
Matrix factorization using the Onco-GPS-Map (30)
showed that three RP factors (signatures) are necessary to
capture variation among RP mRNA levels in normal blood
and brain tissues, with tissue types within the brain strat-
ifying into cerebellar and non-cerebellar associated tissues
(Figure 2A–C), and 16 RP factors are necessary to capture
variations in 53 normal tissue types (Supplementary Fig-
ures S3a, b and S4). Consistently, the three factors for blood
and brain were linear combinations of the 16 factors (Sup-
plementary Figure S3c). Our results validate and build on
previously observed plasticity of RP mRNA expression in
cancers (42,43) and suggest that each normal tissue has a
specific RP mRNA signature, which is a combination of RP
signatures across tissues.
Speculation IIIa: The lack of tissue-specific clustering in
cell lines suggests a universal RP mRNA signature in cell
lines, possibly because of adaptation to in-vitro culture con-
ditions.
Speculation IIIb: Whereas the mRNA data shows clear
tissue-specific RP signatures in normal and cancer tissues,
RPs are known to have extra ribosomal functions (3). One
might wonder whether the tissue-specific mRNA signatures
noted here might reflect these other functions and not the
heterogeneity of ribosomal composition. This is difficult to
test without isolating ribosomes from different tissues and
dissecting their RP content. However, a genomic deletion or
knockout would affect both structural and extra-ribosomal
functions of the RPs. The ability of cancer cell lines and tu-
mor cells to survive in the absence of certain RP genes, while
not ruling out the extra ribosomal effects of RPs, might be
an indication of the existence and functional viability of ri-
bosomes with altered compositions.
Fact IV: Tissue-specificity of RP mRNA signatures was
observed at both the transcription level (RNA-seq data)
and the translation level (ribosome profiling data). A com-
parison of RP translation data from ribosome profiling (i.e.
data on which RP gene transcripts are actually being trans-
lated in the ribosome) and RP mRNA expression data in
matched samples showed very strong correlation between
the two (Figure 7, Supplementary Figures S19 and S20).
This shows that the levels of RP transcripts being trans-
lated in the ribosome are proportional to their mRNA lev-
els. Consistently, tissue and development stage specificity
of RPs were observed not only at the mRNA expression
(Supplementary Figure S20) and translation (Supplemen-
tary Figure S19) levels, but also at the protein levels in a
small dataset (24) of normal human tissues (Figure 8).
Speculation IVa: The simplest conclusion from these data
is that the relative amounts of RP proteins made from the
mRNA are proportional to their mRNA levels and would
reflect in the amounts of these RP proteins used when the
ribosome is assembled. However, it is still possible that
when the ribosome is actually assembled, it always uses the
full complement of 80 RPs and its stoichiometry remains
1:1:1. . . Finally, RPs undergo post-translational modifica-
tions (PTM) which cannot be captured by ribosome profil-
ing or even by many other protein-estimation methodolo-
gies. Such PTMs could buffer the RP variability seen in our
study, or, possibly, further contribute to the heterogeneity
of RP function (58).
Speculation IVb: Interestingly, actual tissues obtained
from mouse (e.g. hippocampus, adipose) and correspond-
ing cell cultures grown in the lab (e.g. hippocampal neu-
ron culture, adipocyte culture) were cleanly distinguishable
in both ribosome profiling (Supplementary Figure S19f–
g) and mRNA expression (Supplementary Figure S20f–g)
data of RP genes, suggesting that there is a difference in the
amounts of RP mRNA that are transcribed and translated
in ribosomes in actual tissues versus their corresponding cell
cultures. This would suggest that the RP protein needs of
cells in culture are different from those same cells in-vivo,
which is an interesting fact in itself.
Fact V: Kidney cancer subtypes, which are known to
arise from different cells of origin (39,40), had distinct RP
mRNA and RP CNV signatures (Figure 3d, Supplementary
Figure S9). Several cancer types had RP subtypes with dis-
tinct RP mRNA signatures (Figure 3). In six of these, the
RP-subtypes exhibited differential patient survival (Figure
4a), and distinct molecular characteristics that mapped well
onto known genomic, histologic, or transcriptomic sub-
types for these cancers (45–49) (Supplementary Figure S11).
In LGG, UVM, and BLCA, the majority of the difference
in RP mRNA levels among the RP subtypes were due to
copy number alteration of RP genes (Supplementary Fig-
ure S12). Significantly, the RP genes RPL5, RPL11, RPL22,
RPS8 on chromosome 1p, and RPL13A, RPL18, RPL28,
RPS5, RPS9, RPS11, RPS16, RPS19 on chromosome 19q
were co-deleted in the better prognosis RP subtype in LGG.
Speculation Va: The fact that deletions of RP genes on
chromosome 1p and chromosome 19q did not abrogate ri-
bosome function in these LGG samples, again points to the
ability of the ribosome to function with loss of some RPs.
These results are important by themselves in the biology of
these tumors. At a minimum, as previously reported (42,43),
the RP subtype signatures are useful biomarkers of progno-
sis for current treatment methods.
Speculation Vb: If the ribosome can retain its function
despite the loss of many structural proteins, perhaps there
are many functionally equivalent but structurally distinct
ribosome types, which can perform the job of translating
mRNA into protein with almost equal efficiency and fi-
delity. Some evidence for this conclusion comes from the
CNV and CRISPR deletion data, which show that dele-
tion of both copies or knockout of RP genes does not
abrogate ribosome function. If this view is correct then
cells/tissues might be choosing a combination of the avail-
able ribosome types to optimize its functions in a dynamic
manner.
Speculation VI: An interesting question that is beyond
the scope of this paper is to understand the mechanisms that
regulate ribosome structural heterogeneity in various cells,
tissues, environments, and development stages. Since RPs
are essential for early development (1) in complex eukary-
otes, this regulation is probably established during embryo-
genesis. This is also consistent with our observation that
RP protein levels are both tissue and development-stage–
specific in normal human fetal and adult tissues.
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Speculation VII: In most cancers, loss of both copies
of some RPs seems to have no effect on survival (Supple-
mentary Figure S16). This suggests that when tumors al-
ter the genomic landscape to survive and grow, some ribo-
some types are lost, and the tumor compensates by using
others, without losing the ability to translate the proteins it
needs. A more interesting possibility is that cancers may de-
liberately alter the choice of which ribosome types they use.
They might even invent novel ribosome types, by altering
RP compositions to enhance translation speed or fidelity of
proteins that they need. If this last possibility is true, then
there may exist ribosome types that are in cancers but not
in normal tissue. This would mean that in a given tissue,
a RP gene may be essential for the tumor but redundant
for the normal tissue. In such a situation, at least in prin-
ciple, drugs similar to antibiotics, which target bacterial ri-
bosomes, might be designed to target cancer specific ribo-
somes. Functional inhibition of tumor specific ribosomes
by locally delivering such drugs may be a novel way to tar-
get cancer in a highly tissue-specific and potentially toxicity
free manner.
Speculation VIII: While the existence of ‘structurally dis-
tinct ribosomes’ can be validated only upon isolation, and
structural, biochemical, and cellular characterization of in-
dividual ribosomes, our study contributes to a growing
body of evidence suggesting the possibility of ‘specialized
ribosomes’ (3,58). Our findings also suggest the existence of
a novel regulatory layer of control, which determines tissue
and development-stage–specific ribosome compositions ei-
ther by establishing them during embryogenesis and/or by
adapting them to the dynamic needs of the tissue over time.
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